Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:08:07 EDT Sat 27 Jul 2024
Enter Symbol
or Name
USA
CA



Q:MDGL - MADRIGAL PHARMACEUTICALS INC - http://www.madrigalpharma.com.
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
MDGL - Q0.2276.05·290.162.3284.49+1.030.4167.847,2315,050287.67  289.9115  276.63299.98  119.760416:01:24Jul 2415 min RT 2¢

Recent Trades - Last 10 of 5050
Time ETExPriceChangeVolume
16:01:24Q284.491.0328
16:01:19Q284.491.0375
16:01:17Q284.491.034
16:01:15Q284.491.0310
16:01:13Q284.491.03386
16:00:56Q284.491.03259
16:00:51Q284.491.03793
16:00:49Q284.491.0337
16:00:47Q284.491.034
16:00:10Q284.491.0342

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-07-24 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Release Second-Quarter 2024 Financial Results and Host Webcast on August 7, 2024
2024-06-06 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra(TM) (resmetirom) Presented at the EASL Congress
2024-06-05 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
2024-05-29 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Present Multiple Rezdiffra(TM) (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
2024-05-07 07:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
2024-04-24 16:00U:MDGLNews ReleaseMadrigal Statement on the Passing of Dr. Stephen Harrison
2024-04-23 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024
2024-04-22 06:00U:MDGLNews Release6 Stocks Positioned to Soar as Investors Focus on MASH
2024-04-16 16:05U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-04-09 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra(TM) (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis
2024-04-03 16:05U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-03-18 23:59U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering
2024-03-18 16:04U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces Proposed Public Offering
2024-03-14 16:15U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces FDA Approval of Rezdiffra(TM) (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis
2024-03-06 16:05U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-03-05 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis
2024-02-28 07:01U:MDGLNews ReleaseMadrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer
2024-02-28 07:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-21 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2024-02-08 08:00U:MDGLNews ReleaseMadrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine